Monitoring of new psychoactive substances in France: update of addictovigilance data
European Journal of Public Health · 10.06.2026 · 36 (4)
DOI: 10.1093/eurpub/ckag106 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Public Health, online erschienen am 16.06.2026. Verfasst von Arnaud Autellet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'addictovigilance Occitanie-Est, CHU Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Psychotropic Drugs, Substance-Related Disorders, Illicit Drugs. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
New psychoactive substances (NPS) represent a growing public health challenge in Europe. Their rapid emergence, chemical diversity and unpredictable toxicity complicate prevention, clinical management and regulatory responses. This study provides an updated overview of NPS-related harms in France using national addictovigilance data. Data were extracted from three complementary surveillance systems: (i) the NotS program of spontaneous reports of NPS-related adverse events (2009–24), (ii) the OPPIDUM survey conducted among users attending addiction care centers (2016–24), and (iii) the DRAMES registry of toxicologically confirmed drug-related deaths (2012–23). Substances were classified by chemical family and clinical effects were coded using MedDRA terminology. In addition to descriptive analyses, regression models were used to assess temporal trends. A total of 3468 NotS involving at least one NPS were recorded, increasing from 5 cases in 2009 to 726 in 2024. Synthetic cathinones and synthetic cannabinoids accounted for nearly 90% of notifications. Trend analyses confirmed a significant increase in NPS notifications and reported use over time. In OPPIDUM, the proportion of NPS users increased from 0.3% in 2016 to 1.7% in 2024. In DRAMES, 136 NPS-related deaths were identified between 2012 and 2023, with no significant overall increase in mortality during the study period. Synthetic cathinones and synthetic cannabinoids dominate the French NPS landscape. The integration of multiple addictovigilance data sources provides a robust framework for early signal detection and supports public health decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre d'addictovigilance Occitanie-Est, CHU Montpellier, Montpellier, France.
- Centre d'addictovigilance Provence-Alpes-Côte d'Azur et Corse, AP-HM, Marseille, France.
- Centre d'addictovigilance Ile de France et Centre, APHP, Paris, France.
- Centre d'addictovigilance Rhône-Alpes Est, CHU Grenoble Alpes, Grenoble, France.
- Centre d'addictovigilance Bretagne Normandie, CHU Caen, Caen, France.
Zitieren
APA
Autellet, A., Lacroix, C., Batisse, A., Micallef, J., Fouilhe, N., Le Boisselier, R., Peyrière, H., Eiden, C., & French Addictovigilance Network (2026). Monitoring of new psychoactive substances in France: update of addictovigilance data. European Journal of Public Health, 36(4). https://doi.org/10.1093/eurpub/ckag106
Vancouver
Autellet A, Lacroix C, Batisse A, Micallef J, Fouilhe N, Le Boisselier R, et al. Monitoring of new psychoactive substances in France: update of addictovigilance data. European Journal of Public Health. 2026;36(4). doi:10.1093/eurpub/ckag106
BibTeX
@article{Autellet2026,
author = {Autellet, Arnaud and Lacroix, Clémence and Batisse, Anne and Micallef, Joëlle and Fouilhe, Nathalie and Le Boisselier, Reynald and Peyrière, Hélène and Eiden, Céline and French Addictovigilance Network, French Addictovigilance Network},
title = {Monitoring of new psychoactive substances in France: update of addictovigilance data},
journal = {European Journal of Public Health},
year = {2026},
volume = {36},
number = {4},
doi = {10.1093/eurpub/ckag106}
}
EUVIMED